Key Documents
Edgar Engleman
- Professor, Pathology
- Professor, Medicine
- Member, Cancer Center
Contact Information
- Clinical Offices
Stanford Blood Center 3373 Hillview Ave MC 5556 Palo Alto, CA 94304 Telephone Work (650) 723-7960 Fax (650) 725-0592
Clinical Focus
- Pathology
- Pathology and Laboratory Medicine
Professional Education
- Stanford Hospital & Clinics (1978) CA USA
- Board Certification: Internal Medicine, American Board of Internal Medicine (1974)
- UCSF Medical Center (1973) CA
- Moffitt Hospital-Ucsf (1972)
- Columbia University College of Physicians & Surgeons (1971) NJ
Postdoctoral Advisees
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.
- Consulting: Globe Immune Inc., Innate Immune Inc., Taiji
- Equity: Capnia Inc., Globe Immune Inc., Innate Immune Inc., Pepgen Corporation, Prestwick Pharmaceuticals
- Service on Board of Directors: Capnia Inc., Prestwick Pharmaceuticals
Research Interests
The goal of this laboratory is to better understand dendritic cell biology with the objective of using this information to discover and develop more effective immunotherapeutic approaches to disease. We pursue this goal by performing experiments in both mice and humans. In our initial clinical studies antigen pulsed dendritic cells were administered to patients with cancer or life-threatening viral infections in order to induce specific immunity. The results of these trials have been extremely encouraging. More recently we have focused our studies on the development and life cycle of dendritic cells, including Langerhans cells, and the results have not only shed new light on dendritic cell biology but also have led to our ability to target dendritic cells in vivo without having to manipulate these cells in vitro. We believe that this new approach will eventually make it possible to downregulate as well as upregulate the immune system in an antigen specific manner.
Clinical Trials
Publications
- Bioconjug Chem. 2009; (1): 111-9
- J Immunol. 2008; (6): 3811-7
- N Engl J Med. 2008; (4): 362-8
- Bioconjug Chem. 2007 Jan-Feb; (1): 77-83
- Blood. 2007; (7): 2484-93
- J Vis Exp. 2007; (10): 484
- J Immunol. 2007; (7): 4608-15
- Blood. 2006; (4): 1383-90
- Clin Cancer Res. 2006; (8): 2568-74
- J Immunol. 2005; (5): 2645-52
- Exp Hematol. 2005; (2): 173-81
- Ann N Y Acad Sci. 2005; 96-104
- Sci STKE. 2004; (241): pe28
- Cytotherapy. 2004; (2): 122-7
- Nat Med. 2004; (5): 510-7
- J Clin Invest. 2004; (5): 774-83
- Nat Immunol. 2004; (1): 45-54
- Clin Immunol. 2003; (1): 10-5
- Semin Oncol. 2003; (3 Suppl 8): 23-9
- Nat Immunol. 2002; (12): 1135-41
- J Virol. 2002; (21): 11033-41
- Blood. 2002; (5): 1676-82
- Blood. 2002; (5): 1517-26
- Biol Blood Marrow Transplant. 2001; (9): 517-22
- J Immunol. 2001; (12): 7150-6
- Ann N Y Acad Sci. 2001; 167-73; discussion 173-4
- Mol Ther. 2001; (2): 186-96
- J Immunol. 2001; (6): 4254-9
- Proc Natl Acad Sci U S A. 2001; (15): 8809-14
- Biol Blood Marrow Transplant. 2000; (6): 621-7
- Annu Rev Immunol. 2000; 245-73
- Blood. 2000; (5): 1865-72
- Science. 2000; (5499): 2152-4
- Transplantation. 2000; (8): 1549-54
- J Immunol. 1999; (1): 560-7
- Clin Immunol. 1999; (1): 67-75
- Blood. 1999; (7): 2411-9
- J Immunol. 1998; (1): 209-17
- Transplantation. 1998; (5): 585-93
- J Infect Dis. 1998; S39-42
- AIDS Res Hum Retroviruses. 1998; (7): 551-60
- Cytotechnology. 1997; (1-3): 1-8
- J Immunol. 1997; (7): 3113-7
- J Immunol. 1997; (4): 1666-8
- J Immunol. 1997; (3): 1115-24
- Eur J Immunol. 1997; (6): 1413-21
- AIDS Res Hum Retroviruses. 1997; (1): 33-9
- Nat Med. 1996; (1): 52-8
- Cell Immunol. 1996; (1): 1-6
- Nat Med. 1996; (2): 183-9
- Immunol Today. 1996; (4): 174-6
- J Immunol. 1995; (2): 578-84
- Immunology. 1995; (3): 467-74
- Eur J Immunol. 1995; (5): 1206-11
- J Immunol. 1995; (9): 4434-43
- J Immunol. 1995; (9): 4423-33
- Arthritis Rheum. 1995; (12): 1826-31
- Annu Rev Immunol. 1995; 201-27
- J Clin Invest. 1995; (1): 296-303
- J Immunol. 1994; (3): 996-1003
- J Exp Med. 1994; (2): 757-62
- Arthritis Rheum. 1994; (9): 1305-10
- J Biol Chem. 1992; (26): 18837-43
- Adv Exp Med Biol. 1991; 71-86; discussion 87-96
- J Biol Chem. 1991; (11): 7233-8
- J Exp Med. 1991; (6): 1451-61
- Clin Immunol Immunopathol. 1991; (2 Pt 1): 202-11
- J Biol Chem. 1991; (19): 12216-22
- J Immunol. 1990; (2): 470-6
- J Clin Invest. 1990; (1): 238-47
- J Immunol. 1990; (1): 32-40
- J Exp Med. 1990; (2): 457-62
- Ann N Y Acad Sci. 1990; 307-17
- J Biol Chem. 1990; (5): 2640-9
- J Clin Invest. 1990; (3): 955-61
- Infect Immun. 1990; (3): 703-10
- J Immunol. 1989; (3): 773-80
- J Virol. 1989; (3): 1451-4
- J Immunol. 1989; (6): 1840-6
- J Biol Chem. 1989; (15): 8459-62
- Transplantation. 1989; (6): 1047-53
- J Immunol. 1989; (12): 4161-8
- N Engl J Med. 1989; (1): 28-33
- Clin Immunol Immunopathol. 1989; (2): 147-59
- J Immunol. 1989; (9): 3038-44
- J Immunol. 1988; (6): 1994-8
- Transplantation. 1988; (3): 540-6
- J Clin Invest. 1988; (2): 538-48
- J Immunol. 1988; (9): 2912-8
- Rheum Dis Clin North Am. 1987; (3): 431-45
- J Immunol. 1987; (10): 3231-5
- J Immunol. 1987; (8): 2585-92
- Vox Sang. 1987; (1): 44-7